Zealand Pharma is a Copenhagen, Denmark-based biotechnology company specializing in the discovery, optimization and development of novel peptide drugs. The company has an expansive and mature pipeline of drug candidates that have been identified through its own drug discovery activities. Zealand Pharma’s focus is in the field of diabetes/metabolic diseases, and its lead drug candidate, Lyxumia 1 (lixisenatide), is currently under regulatory review in various countries throughout the world. For more information, visit the company’s Web site at www.zealandpharma.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: